An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Forimtamig (Primary) ; Forimtamig (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Roche
- 12 Dec 2023 Results (n=48) of biomarker analysis assessing the prevalence and co-expression of these targets like GPRC5D, FcRH5 and BCMA and their association with baseline patient characteristics and response to forimtamig, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 10 Jul 2023 Planned number of patients changed from 400 to 480.
- 10 Jul 2023 Planned End Date changed from 25 Jun 2025 to 15 Aug 2026.